Ramalingan et al reported that the combination of the HDAC inhibitor vorinostat with BelCaP, resulted in grade III/IV neutropenia in 50% of the patients, but in their study the dose of BelCaP was higher than in the present study (Ramalingam et al, 2007a). This evidence concerns the gene HDAC9 and neutropenia.